API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com/news-release/2024/04/24/2868266/0/en/Vivoryon-Therapeutics-N-V-Reports-Full-Year-2023-Financial-Results-and-Provides-Varoglutamstat-and-Strategic-Updates.html
https://www.globenewswire.com//news-release/2024/03/04/2839216/0/en/Vivoryon-Therapeutics-N-V-Provides-Update-on-VIVIAD-Phase-2b-Study-of-Varoglutamstat-in-Early-Alzheimer-s-Disease.html
https://www.globenewswire.com//news-release/2023/10/26/2767091/0/en/Vivoryon-Therapeutics-N-V-Provides-Comprehensive-Progress-Report-for-Ongoing-Varoglutamstat-Clinical-Program-Following-R-D-Event-and-VIVA-MIND-DSMB-Dose-Decision.html
https://www.globenewswire.com//news-release/2023/10/23/2764370/0/en/Vivoryon-Therapeutics-N-V-Reports-Positive-Outcome-from-Independent-Data-Safety-Monitoring-Board-with-Unanimous-Decision-for-VIVA-MIND-U-S-Study-of-Varoglutamstat-in-Alzheimer-s-Di.html
https://www.globenewswire.com/news-release/2023/07/16/2705281/0/en/Vivoryon-Therapeutics-N-V-Shares-Clinical-Development-Update-Highlighting-Progress-of-N3pE-Amyloid-targeting-Small-Molecule-Varoglutamstat-in-Alzheimer-s-Disease.html